Jupiter Neurosciences, Inc.
$0.11 -$0.01 (-6.20%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
A material event was filed (Form 8-K).
8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 27
From its Feb 9 high, the share price fell 82%.
Peak close $0.62 on Feb 9; trough close $0.11 on Jul 27. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -82% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
May 21
The stock moved +32.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 21 -
May 20
The stock moved -35.9% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 20
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.